|
Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis Clinical research trials and Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis. Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis clinical trial. Test subjects typically receive the most expert healthcare available for their Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis  Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis
Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis
For Condition: Inflammation,Vasculitis,Wegener's Granulomatosis
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study will collect fluid and tissue samples from the bronchi (air passages to the lungs) of patients with Wegener's granulomatosis for laboratory examination. Wegener's granulomatosis is a type of vasculitis (blood vessel inflammation) that can affect many parts of the body, including the brain, nerves, eyes, skin, sinuses, kidneys, intestinal tract, joints, heart, lungs and other sites. About 85 percent of patients have lung involvement. The lining of the bronchi (bronchial mucosa) is composed of cells that produce mucus, inflammatory cells, and inflammatory mediators (chemicals produced in response to inflammation). Analysis of these various substances may provide insight into what causes different types of lung problems in Wegener's granulomatosis. Patients between 18 and 75 years of age with Wegener's granulomatosis who require bronchoscopy to evaluate the cause of their lung problem may be eligible for this study. Participants will undergo a bronchoscopy in the hospital intensive care unit (ICU). For this procedure, the mouth and throat are numbed with lidocaine jelly and spray. If needed, a sedative is given for comfort. A small plastic tube (intravenous catheter) is placed in a vein to give medications. A pencil-thin tube is then placed through the nose or mouth into the lung airways to examine the airways carefully. At the time of the bronchoscopy, patients in this study will undergo the following additional procedures: -Bronchoalveolar lavage - Saline (salt water) is injected through the bronchoscope into the air passage, acting as a rinse. A sample of the fluid is then withdrawn and examined for infection, inflammatory cells and inflammatory chemicals. (This may be done as part of the standard medical care procedure.) -Bronchial lavage - This procedure is similar to bronchoalveolar lavage, but less fluid is used to rinse larger airways. -Bronchial mucosal biopsies - A small wire is inserted through the bronchoscope next to the bronchial lining. Forceps at the end of the wire pinch off a small piece of tissue for withdrawal and examination. The patient's heart rhythm and rate and oxygen levels are monitored during the procedure. When the procedures are finished, the patient is monitored in the ICU until the numbing effect of the anesthetic has worn off and then moves to a regular hospital bed for overnight. Patients whose test results show an isolated infection or isolated Wegener's lung tissue involvement and who are being treated or are eligible for treatment under another NIH protocol will be followed by X-ray for improvement of their infection or other lung involvement with treatment. Patients whose infection or lung tissue involvement improves may be asked to undergo a second bronchoscopy as described above, but for research purposes only.
Details: Wegener's granulomatosis is a systemic vasculitis in which parenchymal and/or endobronchial inflammation frequently occur. The purpose of this investigation is to analyze bronchial and bronchoalveolar lavage fluid in patients with Wegener's granulomatosis for the presence of immunoregulatory mediators and pro-inflammatory cytokines. We will also be examining mucosal biopsies in these patients to define the histologic changes, the phenotype of infiltrating leukocytes, and the pattern of adhesion molecule expression that may be present. Such studies could lead to an improved understanding of the pathophysiology of this disease and of its pulmonary manifestations and provide potential directions for future therapy.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Diagnosis of Wegener's granulomatosis based on clinical and histological characteristics. Age between 18-75 years. Bronchoscopy is required as part of their standard medical care. FEV1 is greater than 55 percent of FVC. O2 saturation is greater than 90 percent. EXCLUSION CRITERIA: FEV1 is less than 55% of FVC. O2 saturation is less than 90%. Abnormal PT, PTT, or platelet count less than 50. History of adverse reaction to lidocaine or other local anesthetics. Pregnancy.
Total Enrollment: 25
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960065; 96-I-0065
Study Start Date: April 23, 1996
Record last reviewed: January 10, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001541
Other Inflammation Studies:
1. Assessment of Lung Inflammation in Patients with Atopic Asthma Using Positron Emission Tomography
2. Diagnostic Effectiveness of Virtual Bronchoscopy
3. Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
4. Treatment of Wegener's Granulomatosis with Cyclophosphamide
5. Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis
Related Studies:
Other Inflammation Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis
|
|
|
|
|
|
|
|
